Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2005

View Archived Issues

The MVA.HIVA vaccine shows immunogenicity in HIV-infected patients

Gadoversetamide improves MR detection of myocardial infarction

In vivo antimalarial efficacy of methylene blue

EntreMed reports progress in oncology programs

CA4P enhances activity of Avastin in preclinical studies

BDF-9148 benefits adult but not neonatal rabbit hearts after myocardial stunning

Nanocrystalline silver effective against resistant bacterial strains

TopoTarget acquires G2M Cancer Drugs

Nanoparticles facilitate targeted delivery of antirestenotic therapeutics in a porcine model

MYO-029 studied in new phase I/II trial for muscular dystrophy

Pharmexa and BN ImmunoTherapeutics enter license agreement

New phase II study of Orathecin plus gemcitabine for pancreatic cancer

Neuren and Metabolic Pharmaceuticals to codevelop neuroregenerative peptides

Biopolymer Engineering changes name to Biothera

Follow-up candidates identified in peptide deformylase inhibitor collaboration

Pralmorelin protective in ischemia/reperfusion injury in dogs

Salix and Altana sign Xifaxan copromotion agreement

ODAC recommends against approval of Combidex

Hexvix now available in Sweden

Chiron reaches settlement agreement with Respiratory Disease Network

NeoRx private placement funding gives boost to NX-473 development

Tysabri investigator confirms case of PML

ACP-103 safe, well tolerated in patients with Parkinson's disease

Novel hormone-sensitive lipase inhibitors synthesized by Novo Nordisk

Abilify receives new approval

NicOx discloses the development of new ACE inhibitors

Scientists at Sigma-Tau report the discovery of novel glucose/lipid lowering agents

Chemokine CCR-5 receptor antagonists claimed by Schering

Janssen researchers describe a series of selective androgen receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...